Astellas Pharma Inc., Immuno-Biological Laboratories Conclude Licensing Agreement For Anti-Human Osteopontin Antibody

Tokyo, Mar 24, 2006 (JCN) - Astellas Pharma announced on March 23 that it has concluded a licensing agreement with Immuno-Biological Laboratories (IBL) for anti-human osteopontin antibodies includgin 2K1. Osteopontin is a protein implicated in autoimmune diseases including rheumatoid arthritis, bone diseases and cancer metastasis.

Back to news